is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's Friday, and our move up probably caught a few MMs off guard. They needed to keep the price down today so they could go into the weekend flat. Next week we should see modest gains. But it really is going to churn sideways mostly until the efficacy test comes out.
They could drop a few hammers in the mean time, but you saw how short lived the 8-K news was this morning. Everyone is waiting for the efficacy test results.
IMHO if they did an 8-K with details of the MMJ consultancy agreements they've signed with 3 States it would be a major deal.
Saw it on this board actually. The provisional patent application images. I only see the PTSD and Migraine ones now, but it was there before.
4. is a suppository, which apparently works well for Crohn's disease.
Also, I believe they filed a provisional patent for a cannabis laced condom to treat ED.
Comments from someone on Reddit who attended the Canadian Cannabis Investor Conference:
Emblem Gordon Fox, CEO. It was probably one of the most interesting presentation because he shared his thoughts on many topics. He did not try to sell emblem and did not talk about the rec market. For example, he explained the complexity of a greenhouse and said that building new facilities is cheaper then converting a old building. He also said the future of the cannabis medical market is in Pharma. Smoke bothers a lot of people and a lot of patient would relief their pain with Cannabis if they did not have to smoke the product. He made me realized that dry flower is not the future of the medical marijuana. I am not sure how Emblem will position themselves on the market, he did not really talk about the company itself. he mentioned that one of challenge in Pharma is the access to the market through the doctors as only 3% of them prescribes Cannabis products. Also said that Extracted product will be more profitable than dry. Edible will be a good market, but it is not for soon because there is a health risk (lack of knowledge).
The IRB protocol was first approved by the hospital which will perform the safety study and after obtaining its approval the IRB protocol is being submitted for approval to the national IRB committee. The national IRB committee is scheduled to ensemble at the beginning of December 2016.
Upon the expected approval of the safety protocol by the national committee, the company will immediately engage with the study which will last approximately 12 weeks.
The Safety study is designed to test multiple escalating doses to determine the safety and tolerability of the medical grade cannabis cream on healthy volunteers. The psoriasis topical crème infused with active cannabinoids is a unique delivery-system product of OWC designed to be used for skin diseases, where the first application will be tested for safety and efficacy for Psoriasis. The efficacy studies have already been started and results are expected by the end of Jan 2017.
http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-to-submit-psoriasis-topical-cream-irb-safety-protocol-to-the-israeli-national-irb-helsinki-committee-601267666.html#continue-jump
Efficacy test results are due by March. This isn't the FDA, it's the IRB. They could release results at any time. If you are on the sidelines you could miss the boat completely.
Once efficacy results are public this is never going to see .70 again.
I know where I expect the stock to be in six months, but 3 years is a long way out.
So, let's put down some assumptions:
OWCP will be selling it's creme for psoriasis, acne and dermatitis, generating perhaps $7 Million a month, or $84 Million a year.
OWCP will be licensing it's four proprietary delivery systems to other companies. Revenue? No idea, but I like round numbers so I'll go with $10 Million a year.
OWCP already has consulting contracts with 3 MMJ states. No idea on revenue yet (looking forward to that 8-K!), but assuming the trend of legalization continues, more states will vote to legalize MMJ and OWCP will pick up several more State contracts. Total guess, but I'll say $1 Million a year.
So that's $95 Million Revenue by 140 Million shares, so .67 cents per share. No idea about earnings, but OWCP is pretty damn lean so profit ratio will be plump. Also no idea what PE ratio to use, because OWCP is sorta a biotech and sorta a pharma. But based on the $95 Million in annual revenue, I'd say $10 a share is very reasonable and conservative.
HOWEVER, the Ace up OWCP's sleeve is the:
Multiple Myeloma (Cancer)
• Designed to be an Orphan Disease study approved by the FDA
• In-vitro study completed 06/2015 – Cannabis kills the MM cancer cells
• Pre-clinic study on mice completed 12/2015 – calibration phase for dosage,
found most effective ratio of active cannabinoids THC/CBD
• In-vitro study for a combination of 4 approved drugs with cannabis completed
05/2016 – promising results
• Pre-clinic study for the most effective combination on mice with new cannabis
extracts. On-going testing.
• SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL
SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE
DESIGNATION
Honestly, can you please do some DD before you post again. You're just gonna get yourself Ignored if you keep posting nonsense with zero facts and analysis. I'm embarrassed for you.
Likely to see an increase in biotech M&A in 2017:
"NEW YORK, NY / ACCESSWIRE / January 27, 2017 / The Biotech Industry witnessed a drop in mergers and acquisitions (M&A) activity amidst a slump in 2016. The Nasdaq Biotech Index declined roughly 22 percent in 2016. M&A activity within the Biotech Industry totaled 326 deals worth approximately $91 billion in 2016, compared to $118 billion the year prior, according to Bloomberg. Also the number of M&A deals in the sector in 2016 was the lowest total in six years. Research & development productivity of 12 of the biggest biopharma companies, which was measured by annual projected R&D returns, hit a 7 year low in 2016, according to a recent study completed by Deloitte. With many large firms having more cash available, giving them plenty of firepower for larger number of in M & A activities in 2017."
http://finance.yahoo.com/news/biotech-m-activity-expected-rise-150000053.html
Knowledge is power. Stay Long. No reason to part with a single share with Efficacy test results coming soon. In a year, $OWCP will be uplisted and we'll have a lot less MM manipulation.
"MMs have a vast resource of tactics and it would take probably more than my lifetime to figure them all out.
So how do investors somehow manage to overcome the obvious deception in OTCBB arena? One answer is indirection trading style by going long which the MMs do not expect. In the war between investors and public companies on the OTC BB vs the MMs, if the MMs have all the advantages due to position or other factors, direct confrontation such as momentum or day trading hitting the stock is a definite death sentence.
However, an indirect approach tends to weaken the path of least resistance before slowly overcoming it. The most effective way is long-term investors slowly accumulating and holding thus drawing the MMs out of its defenses making them as naked as their short position. This is war so this slow accumulation and holding for the long term easily achieves the desired effect to force MMs to cover and knock off the tactics or bury themselves deeper.
The MMs when caught will especially use every trick and tactic in the book to get a Bear Raid thus playing on the individual fear of most people. The MMs feel they have information and position advantages over the investors as long as the holding of the stock is in weak hands or short term holders. Since they are OTC BB MMs who believe all OTCBB companies are not worth investing and management is ineffective regardless what is happening within the company. Furthermore, MMs know they are in the position to impose a great deal of influence in OTC BB stocks trading when it suits their needs.
This inherent power of position enables the MMs to move the markets at any time up or down. As a result, the only way to draw them out of their favorable position is going long. Now this does not mean just any company but to effectively nail the MMs, Longs must find the great company on the floor and accumulate long before the MM tactics and games begin."
https://www.reddit.com/r/weedstocks/comments/1xydch/market_maker_speaks_out_ways_of_a_market_maker/
I'm Long on OWCP for the fundamentals, like the growing executive team, the knowledge and experience base, the delivery systems, and the 8 patents.
However, I know many people subscribe to Technical Analysis, so here's a useful site:
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=OWCP
Please take this with a grain of salt, however, as TA can be easily manipulated by MMs on OTC stocks.
Are you a Millennial? Is this how Millennial's trade? Can someone send Traderbx a Participation Trophy before he starts to cry?!?
It should take you less than 30 seconds to research this:
https://www.otcmarkets.com/stock/OWCP/news
Look at News and SEC Filings, and compare that to a chart of the stock price.
Your broker has to allow after hours trading.
Mine doesn't. : (
Curious what valuation you put on OWCP once they are generating $2-4 Million a month in psoriasis creme sales?
Curious what valuation you subscribe to the consulting deals OWCP has signed with 3 MMJ States?
Dr Baruch has personally overseen treatment of nearly 12,000 cannabis patients. There simply is no other MMJ Head of Science with his experience and depth of knowledge.
That is why OWCP has already signed contracts with THREE MMJ States. No other MMJ stock has that, not to mention the four delivery systems, two of which are ready to go, and the patents filed for PTSD and Multiple Myeloma.
OWCP has released the roadmap to success. Stay Long and stay Strong. The MMs will test our resolve daily.
Nice research!!!
"OTC BB market makers (MMs) don't use fundamental and technical analysis. However, what they do realize is a lot of dumb money does use this newest nitch charting or TA (Technical Analysis) to run a stock either up or down. To the MMs this is like taking candy from a baby. Simply they will paint the tape and use whatever tactic to affect the charting bands. Thus the public and dumb money they will have eating out of their hands. Effectively the MMs can show a strong stock growing weak by manipulating the close price in order to generate selling volume, delaying trading time to manipulate trading activities, or even stalling the ask without honoring orders to hold a stock price."
https://www.reddit.com/r/weedstocks/comments/1xydch/market_maker_speaks_out_ways_of_a_market_maker/
"MMs have a vast resource of tactics and it would take probably more than my lifetime to figure them all out.
So how do investors somehow manage to overcome the obvious deception in OTCBB arena? One answer is indirection trading style by going long which the MMs do not expect. In the war between investors and public companies on the OTC BB vs the MMs, if the MMs have all the advantages due to position or other factors, direct confrontation such as momentum or day trading hitting the stock is a definite death sentence.
However, an indirect approach tends to weaken the path of least resistance before slowly overcoming it. The most effective way is long-term investors slowly accumulating and holding thus drawing the MMs out of its defenses making them as naked as their short position. This is war so this slow accumulation and holding for the long term easily achieves the desired effect to force MMs to cover and knock off the tactics or bury themselves deeper.
The MMs when caught will especially use every trick and tactic in the book to get a Bear Raid thus playing on the individual fear of most people. The MMs feel they have information and position advantages over the investors as long as the holding of the stock is in weak hands or short term holders. Since they are OTC BB MMs who believe all OTCBB companies are not worth investing and management is ineffective regardless what is happening within the company. Furthermore, MMs know they are in the position to impose a great deal of influence in OTC BB stocks trading when it suits their needs.
This inherent power of position enables the MMs to move the markets at any time up or down. As a result, the only way to draw them out of their favorable position is going long. Now this does not mean just any company but to effectively nail the MMs, Longs must find the great company on the floor and accumulate long before the MM tactics and games begin."
https://www.reddit.com/r/weedstocks/comments/1xydch/market_maker_speaks_out_ways_of_a_market_maker/
Market Makers. Days like today can be demoralizing. But stay Long and stay Strong.
Market Makers have a very, very long history of putting their own profit making interests above the interests of the market. Check out this SEC filing from 1996:
B. MISCONDUCT IN THE NASDAQ STOCK MARKET
The Nasdaq market has not always operated in an open and
freely competitive manner. Nasdaq market makers have engaged in
conduct which has resulted in artificially inflexible spreads
between dealer price quotations for many Nasdaq securities and
unduly disadvantageous prices to investors trading in those
securities. A number of Nasdaq market makers have also taken
action to discourage competition. At the same time, various
Nasdaq market makers have coordinated price quotations,
transactions and transaction reports in order to protect or
advance their proprietary interests, to the detriment of
investors and other market participants. Many Nasdaq market
makers have also failed to satisfy their basic obligations to
transact at quoted prices and to report transactions in a timely
and accurate manner. These activities involved potentially
serious violations of NASD rules and the federal securities laws.
Sorry for the shameless self promotion, but I think today's 8-K addresses my Milestones prediction number 5:
12 Milestones for 2017
1-3. Generate revenue via worldwide psoriasis cream sales, posting sales figures for Q2, Q3, and Q4.
4. Seek fast-track approval for testing cream on other skin ailments, such as eczema, rosacea, seborrheic dermatitis, and acne (?). With safety testing already completed on the formulation for psoriasis, approval for testing for other skin conditions should be expeditious. Approval for alternate use trials by Q3 seems plausible to me.
5. With money coming in from cream sales, have OWCP retain a top IP law firm such as Ropes & Gray or MoFo to assist with patent protection and licensing agreements.
6. Secure additional financing to accelerate the pace of sublingual treatment trials. With revenue coming in, secure a line of credit or seek an investment from a private equity firm. Just like having Emilia Cosmetics and Medmar putting up $300,000 each was a vote of confidence in OWCP, having JPM issue a $10 Million line of credit or having a private equity firm like Apollo taking a small stake would put OWCP in league with big board biotech companies.
7. Uplist. Once OWCP is trading steadily over $1, seek counsel to uplist.
8. License sublingual tablet to other biotech companies. Success begets success. Once OWCP is better known, expect companies to come out of the woodworks and pay licensing fees for the sublingual tablet. With each successful deal inked, a press release of “Company X is please to announce it has entered into an agreement with OWC Pharmaceuticals to license OWCP’s sublingual tablet technology, which Company X will use in clinical studies for it’s trails of XYZ to treat [disease]. Company X CEO blah blah said, “We are so excited to license OWCP’s delivery mechanisms as it allows very precise control of dosing. Inhaling cannabis in a doctors office is crude and unscientific…” will be a monthly occurrence.
9. Gain approval for multiple myeloma trials in humans.
10. Gain approval for study of formulation to treat fibromyalgia in humans.
11. Gain approval for study of formulation to treat PTSD in humans.
12. Gain approval for study of formulation to treat migraine in humans.
So there you have it, a very plausible list of 12 hammers that OWCP can easily drop in 2017. I’m having fun imagining what each and every one will do to our share price!
Go $OWCP!
My underlines:
Ms. Sani, who received an MSc [Master of Science Degree) in Chemistry from the Technion – Israel Institute of Technology, Haifa, Israel, will advise OWC's management on the transition of its innovatively-developed cannabinoid products and delivery systems developed internally and through its hospital relationships, to full industrial and commercial production, in strict compliance with all local and state regulations and protocols, working closely with applicable healthcare agencies and ministries. Ms. Sani will also supervise all manufacturing facilities of third party licensees to assure for quality control in accordance with OWC protocols that were developed at leading hospitals in Israel, for a steady and long-lasting quality of products and measured dosages.
Ms. Sani is the CEO and owner of "Shefa Amirim" Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. Shefa Amirim provides clients with the requisite regulatory plans, designing and conducting the required clinical studies, CRO services and the preparation of technical files and and related services necessary for FDA applications and approval. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OBYOGN and IVD's through both regulatory affairs and clinical studies.
Mr. Alon Sinai, OWC's Chief Operating Officer commented on Ms. Sani's appointment, stating that "after investing more than two years in research and development of new cannabinoids treatments and delivery systems, we are extremely excited to move into commercial production of our medical cannabis products. Ms. Sani's unique expertise and vast experience supervising such commercialization transitions will facilitate our ability to enjoy a smooth transition while maintaining and following all applicable regulations. We are thrilled to welcome Ms. Sani to our Advisory Board."
I know, it makes me laugh my *ss off when people say OWCP is a P&D. What sort of P&D volunteers to go in front of a bunch of MBAs and asks them to look at the company.
"It's going up!" "It's going down!" is all just speculation.
What is a FACT is that the psoriasis cream has efficacy resultings coming either end of Jan or March 2017.
What is a FACT is that deals to get the psoriasis cream to global markets are already signed and just await the efficacy and Helsinki safety results.
IT is a FACT that OWCP will switch from a pre-clinical biotech to revenue generating biotech in 2017.
Look at the charts of any MMJ stock that published efficacy results. Can anyone show me a chart of a MMJ stock that released efficacy results and then dropped? Can anyone show me a MMJ biotech stock that has revenues that is trading at .65 cents?
I believe they are in the US now, perhaps signing even more deals. OWCP doesn't pump out PR. They state the facts in 8Ks.
OWCP can release so many 8K's this year:
Efficacy test results for psoriasis creme.
Final safety test for psoriasis creme.
Start of FDA Phase 1 trial.
Disclosure of consulting contracts.
Start of tests for CBD creme for other skin disorders like dermatitis and acne.
Licensing agreements for the creme, sublingual tablet, and/or nasal spray.
They have already inked 3 consulting deals to help, I'm assuming, States with newly legalized MMJ markets. If the consulting deals are not with States, then they are will companies to use OWCP's delivery methods. Either way, we'll see 8Ks soon with the details.
IF you'd bother to read the deals they inked, once they have IRB approvals on the psoriasis creme they can begin sales in EU and perhaps in certain US States. You obviously know nothing about people who suffer from psoriasis, because they will be willing to try any new treatments that hit the market.
OWCP is so much closer to turning a profit than any other MMJ company. The knowledge base at OWCP is staggering. Name one other MMJ company that has a head of science who has personally overseen the MMJ treatment of nearly 12,000 patients. I'll be waiting.
Trump is a huge supporter of Israel. This will be huge for the US MMJ market.
Once revenue starts pouring in, there will be no stopping OWCP.
We know they signed three consulting contracts (I'd love for those to be with CA, FL and/or MA!), so money and possibly even licensing agreements will come from that. We know 2 companies ponied up $300K each to manufacture, distribute, and market the topical psoriasis creme; so all OWCP has to do is cash the checks!
Once revenue starts pouring in OWCP is going to kick into high gear, likely beef up staffing, and it's going to be a very exciting and enriching ride! Hammer after hammer will drop once the engine is purring.
Heck, Trump's FDA appointment alone could send all MMJ stocks flying.
Analysts targets were for $30.43.
It all comes down to due diligence.
OWCP has been careful, calculated and strategic in all their moves and it shows in the 8Ks. They ink a deal with a manufacturer/distributor where OWCP is paid $300,000, and OWCP takes that money to pay for final IRB clinical trials.
I was looking at another MJ stock, pre-revenue, that's trading in the .90 range. Wow, they had a lease for about $2,500 a month for a grow area in NV and what to they do? Drop $100K to buy the place. Instead of keeping that capital for growth, they pre-paid their rent for two years. Genius. That's the hallmark of OTC Stinky Pinkies. The owners pay $$$ for top real estate, and pay themselves $$$ too. Then, when revenues don't hit their rosy expectations, they lower their pay and find a cheaper office space, all the while congratulating themselves for "drastic cost cutting". Total. F*cking. Joke.
I'm about to sell stock in one of my other MJ growers, and was looking at putting it into a NASDAQ MMJ company based in CT. Pre-revenue company, let's see how much the CEO is paying himself: $750,000. Wow, f*cking genius. They'll have to issue more stock soon to they can actually pay for the next FDA trials and for the management team's ski houses.
And that takes me back to OWCP, where management has been paying themselves a very modest $12,000 a year because they know they will be rewarded for their hard work through their stock holdings. As stockholders, we are in the same boat they are. If they get rich, we get rich. I like that a lot and I'll be holding my OWCP stock for years to come.
Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
Good read:
https://www.thestreet.com/story/13962533/1/cannabis-stocks-do-not-trade-on-earnings-instead-on-pipeline-of-drugs.html
I believe there are 2 studies in Israel and one in the US.
July is FDA phase 1.
Efficacy was supposed to be end of Jan.
Final safety is March.
My understanding creme can be sold in EU after efficacy and safety.
Very light volume (1.3 million shares so far). Trading sideways.
I'm not expecting anything exciting until the Israel efficacy study results are out. Annual letter said end of Jan on that, but the new PowerPoint listed March.
Very light volume (1.3 million shares so far). Trading sideways.
I'm not expecting anything exciting until the Israel efficacy study results are out. Annual letter said end of Jan on that, but the new PowerPoint listed March.
Exactly, waiting for that hammer to drop and watch it fly!
They can drop so many hammers this year, it makes every trading day exciting.
Q3 and Q4 revenue numbers from EU psoriasis creme. Note that the EU market for psoriasis is larger than the US market (those PowerPoint numbers only projected US sales as far as I could tell).
Phase 1 of the Multiple Myeloma study.
Studies of creme on other skin conditions.
Consulting contracts with the latest MMJ States, which could very well lead to arrangements where MMJ is offered via OWCP's proprietary delivery systems, with revenue sharing with the State.
So assume worst case he did something inappropriate. The IP is owned by OWCP, not him. He leaves OWCP and they find a new head of the science division. So, even if the story had merit, it would have minimal and temporary impact on the bottom line.
Stories that start with "suicidal woman claims inappropriate relationship" are to be taken with a proverbial grain of salt.
Article from May 2016 that I have to pay $1 to read. LOL
CannaTech 2017 in Tel Aviv, March 20-22. OWCP's Advisory Board member Jeffrey Friedland is a speaker.
https://www.canna-tech.co/home
It is indeed Huge!
You never see a pump & dump company intentionally go in front of a bunch of wealth, smart, sophisticated investors because they would immediately see through the hype. Pump & dump stocks don't want people with Finance degrees asking them tough questions.
This is OWC Pharma going out, telling their story, letting people know that the UK and Canada aren't the center of the MMJ world.
Very impressive!